SCHEMBL4002335

SCHEMBL4002335

Fc1ccc(C(F)Br)c(F)c1F

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.42
CES1 P23141 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4112644 0.79
SCHEMBL5096643 0.79 HDAC4 (0.33) CES2CES1
SCHEMBL27588800 0.79 CES2 (0.45) CES2CES1
SCHEMBL27826253 0.78 CES2 (0.41) CES2CES1
SCHEMBL1600457 0.78 CES2 (0.44) CES2CES1
SCHEMBL5089366 0.76 HPGD (0.31)
SCHEMBL28974571 0.75 CES2 (0.42) CES2CES1
SCHEMBL1201506 0.75 CES2 (0.52) CES2CES1
SCHEMBL578144 0.75
SCHEMBL10779530 0.75 CES2 (0.42) CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1883619-B1 PROCESS OF PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY APPROVED SALTS CHOONGWAE PHARMA CORP (KR) 2013-03-20 EP disclosed
US-7495126-B2 Process of preparation of substituted tetrafluorobenzylaniline compound and its pharmaceutically approved salts CHOONGWAE PHARMA CORPORATION (KR) 2009-02-24 US disclosed
US-20080167492-A1 Process of Preparation of Substituted Tetrafluorobenzylaniline Compound and Its Pharmaceutically Approved Salts CHOONGWAE PHARMA CORPORATION (KR) 2008-07-10 US disclosed
EP-1883619-A1 PROCESS OF PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY APPROVED SALTS Choongwae Pharma Corporation (KR) 2008-02-06 EP disclosed
WO-2006126846-A1 PROCESS OF PREPARATION OF SUBSTITUTED TETRAFLUOROBENZYLANILINE COMPOUND AND ITS PHARMACEUTICALLY APPROVED SALTS CHOONGWAE PHARMA CORPORATION (KR) 2006-11-30 WO disclosed
US-20050192359-A1 N-biphenylamides and fungicidal compositions containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-01 US disclosed
EP-1486483-A1 N-BIPHENYLAMIDES AND FUNGICIDAL COMPOSITIONS CONTAINING THE SAME Sumitomo Chemical Company, Limited (JP) 2004-12-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050192359-A1 N-biphenylamides and fungicidal compositions containing the same CBR3, ARNT, CBR1 CES2 1280/4885CES1 1297/4885
US-20080167492-A1 Process of Preparation of Substituted Tetrafluorobenzylaniline Compound and Its Pharmaceutically Approved Salts IL5, CYP3A5, PGA5 CES2 3381/4885CES1 4330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.